L-Acetylleucine is enantiomer of Acetylleucine that used in the treatment of vertigo and cerebellar ataxia. The N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar and even better than that observed under treatment with the racemate component only. Acetylleucine was aggressively marketed in France for vertigo. It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have ‘anticalcium’ properties on neurotransmission. Pierre Fabre conducted clinical studies of L-Acetoleusine for Vertigo and Dizzinesstherapy. However, all clinical studies were discontinued

Sodium acetate C-11 (C-11 acetate) Injection is a radiopharmaceutical commonly used for clinical studies with positron emission tomography (PET). It is used as a PET radiotracer for imaging cancer cells via incorporation into intracellular phosphatidylcholine membrane microdomains in cancer cells. Positron emission tomography using carbon-11 acetate (AC-PET) may help find local or distant metastases from prostate cancer. C-11 acetate is taken up in proportion to fatty acid synthesis. It is also taken up proportionally to myocardial blood flow, and therefore myocardial oxygen consumption. In rodents, there is clearance from all organs except the pancreas within one hour. Tumor uptake was clearly visible in 30 minutes. In humans, more than 80% of tracer is cleared from normal tissues within 20 minutes.It is taken up in cancer within the prostate and prostate cancer metastases, however, it has been reported that increased uptake can be seen in hyperplastic and benign prostate tissues. No urinary excretion is seen. No toxic effects have been demonstrated. The ongoing clinical trial NCT01530269 is studying how this imaging test may help influence the choice and extent of initial treatments, and subsequent treatments of prostate cancer.